IceCure Medical Ltd. ICCM
IceCure Medical Ltd. (Nasdaq: ICCM) is an oncology medical device company. Its next catalyst on record is XSense system with CryoProbes: Submit Medical Device Regulation (MDR) approval application (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: XSense system with CryoProbes — Submit Medical Device Regulation (MDR) approval application (H2 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ProSense cryoablation system | breast cancer and other tumors | device-combination | NA_NON_THERAPEUTIC |
| XSense system with CryoProbes | multiple (same as ProSense) | device-combination | NA_NON_THERAPEUTIC |
| MSense | multiple/larger tumors | device-combination | NA_NON_THERAPEUTIC |
Recent results and decisions
- Oct 13, 2026positive IceCure reports 12-month clinical data showing 97.5% objective response rate among 40 patients treated with cryoablation plus endocrine therapy and 91.7% among 24 patients treated with cryoablation alone.
Featured presentations included 12-month clinical data reporting objective response rates of 97.5% among 40 patients treated with cryoablation plus endocrine therapy and 91.7% among 24 patients treated with cryoablation alone.
Filing - Sep 10, 2026approval China NMPA granted Class III medical device approval to market ProSense system and cryoprobes (ex-US regulator).
today announced that it has received approval, as a Class III medical device, from China’s National Medical Products Administration (“NMPA”) for its ProSense® system and associated cryoprobes.
Filing - Mar 25, 2026positive Single-arm ICESECRET (n=114) 5-year top-line: 83.9% recurrence-free at median 4-year follow-up; 89.4% in subgroup with tumors <=3 cm and no prior kidney cancer.
The study demonstrated that 83.9% of patients were recurrence-free at this median follow-up period.
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other oncology companies
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- NovoCure Ltd NVCR
- Personalis, Inc. PSNL
- AnaptysBio, Inc. ANAB
- Freenome, Inc. FRNM
- Alpha Tau Medical Ltd. DRTS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.